
Opinion|Videos|September 6, 2023
Evolving the Standard of Care for AD: Safety and Treatment Response
Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.
Advertisement
Episodes in this series

Christopher Bunick, MD, PhD
Associate Professor, Dermatologist
Yale University
Middlebury, Connecticut
Ruth Ann Vleugels, MD, MPD, MBA
Vice-Chair of Academic Affairs
Department of Dermatology at Brigham and Women’s Hospital
Boston, Massachusetts
Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).
Segment Description: Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
2
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
5





























